RxDoctor Payments Data

Misty Maxwell

Family · Cherokee, ALNPI 1932651478

Payments from drug & device makers

$961in general payments, 2019–2025

Across 55 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$264
  • Astellas Pharma US Inc$209
  • AbbVie$144
  • AstraZeneca$128
  • Novo Nordisk$104
  • Genentech USA, Inc.$29
  • plus $83 from 5 others

What the payments were for

  • Food & beverage$77681%
  • Education$18519%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$961 in reported general payments places this provider in the 65th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$31,647
Medicare patients
107
Services billed
2,699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide84$90,753
EliquisApixaban79$55,749
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$35,564
FarxigaDapagliflozin Propanediol45$33,032
JanuviaSitagliptin Phosphate36$27,711
TrulicityDulaglutide19$18,304
JardianceEmpagliflozin23$17,347
EntrestoSacubitril/Valsartan25$17,003
OzempicSemaglutide13$14,350
Dexlansoprazole DrDexlansoprazole42$8,947
MyrbetriqMirabegron14$7,782
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,017
SymbicortBudesonide/Formoterol Fumarate15$4,548
Celecoxib131$4,114
Gabapentin205$2,888

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$22$109,057103 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$128$44,59771 claims
GSKTrelegy Ellipta$264$35,56449 claims
Boehringer IngelheimJardiance$13$17,34723 claims
Novo NordiskOzempic$104$14,35013 claims
Astellas Pharma US IncMyrbetriq$209$7,78214 claims
AbbVieSynthroid$144$78219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,415 family providers in Alabama.

Other family in Cherokee

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →